September 19, 2019
Mochida Pharmaceutical aims to rack up peak sales of several billion yen with its soon-to-launch biosimilar version of Forteo (teriparatide), which will be the first follow-on biologic in the Japanese osteoporosis market, Executive Managing Director Junichi Sakaki tells Jiho. The...read more